ESMO E-Learning: 2013 Highlights in NSCLC

Learning Objectives

  • To provide a general update on novelties in the treatment of patients with non-small cell lung cancer and put the clinically meaningful findings into perspective
  • To provide an update on the latest findings related to Mutations testing
  • To provide an update on the latest clinical research findings on targeted therapies, including patients with EGFR mutations, approaches to overcome ALK resistance, Antiangiogenic treatments, immunotherapies and therapies that target other molecules

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
2013 Highlights in NSCLC 33 min. 43 slides 1 Take Test
Martin Reck
Read more
Niels Reinmuth
Read more

The oncology community is faced with some significant results from clinical trials, mainly in patients with non-small-cell lung cancer (NSCLC) and therefore there is the strong need to summarise what has been achieved in this field. This E-Learning module is intended to show, from the clinical perspective, some of the most important results in NSCLC presented at main oncology events in 2013. Physicians who treat patients with NSCLC, and who need to keep pace with the rapid research advances, will welcome such a Module that gathers together and presents all the latest important information.

The module is divided into two parts. The first part deals with diagnostic tests and covers results from the Lung Cancer Mutation Consortium, which showed that treatment with therapies matched to oncogenic drivers, improves survival in patients with lung cancers. Last year a new Gene fusion in lung cancer was discovered; small subset of adenocarcinomas without other common oncogenic alteration demonstrated NTRK1 gene fusions which lead to constitutive activity of the TrkA kinase activity.

The second part of the module, on the latest results with targeted therapies, covers the treatment of patients with EGFR mutations, therapeutic approaches to overcome ALK-resistance, Antiangiogenic treatment, immunotherapies and therapies that target other molecules. In particular:

  • Patients with EGFR mutations: the authors elaborate on results with afatinib
  • Therapeutic approaches to overcome ALK-resistance: the authors cover results with a highly selective ALK inhibitor CH5424802 and a potent and selective oral ALK inhibitor LDK378
  • Research results with antiangiogenic treatment: the authors cover studies with bevacizumab and nintedanib
  • Immunotherapies: the authors cover the latest findings with Antigen dependent immunotherapies (L-BLP25 and vaccination with belagenpumatucel-L) and antigen independent immunotherapies (nivolumab and MPDL3280A)
  • Other targeted agents: the module covers the findings of phase III study with MET inhibitor tivantinib

For each of the above mentioned agents, apart from covering the mechanism and key pathways implicated in the activity, the authors provide key efficacy results and safety profile.

For all those who may have missed for any reason even a piece of unprecedented level of clinically relevant information from studies in NSCLC presented last year, this E-Learning module is the perfect and easiest way to keep in tune with highlights on the progress achieved.

This E-Learning module was published in 2013 and expired in 2016.

Last update: 18 April 2014

Prof Reck has reported to have received honoraria for lectures and advice from Hoffmann-La Roche, Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca and Pfizer. Prof Reinmuth has reported receiving speaker’s honoraria from Roche, BMS, Lilly, Boehringer Ingelheim and Novartis.